Key Takeaways: How Mounjaro Works

Dual receptor agonist: Activates both GIP and GLP‑1 receptors – a unique mechanism.
Appetite regulation: Acts on brain centres to increase fullness and reduce cravings.
Blood sugar control: Enhances insulin only when glucose is high, minimising hypos.
Once‑weekly dosing: Long half‑life (~5 days) due to albumin binding.
Weight loss: Slows gastric emptying and reduces calorie intake.
Proven efficacy: Clinical trials show up to 20% weight loss in people with obesity.

Mounjaro (tirzepatide) works by mimicking two natural hormones that regulate blood sugar and appetite. This dual action makes it highly effective for both type 2 diabetes and weight management. Below we explain the science behind its effects.

Important Medical Advice

If you experience severe abdominal pain that radiates to your back (possible pancreatitis), difficulty breathing, or swelling of the lips/tongue (severe allergic reaction), seek immediate medical help. Always discuss new symptoms with your doctor.

Chemical Composition & Molecular Structure of Mounjaro

Tirzepatide, the active ingredient in Mounjaro, is a synthetic linear peptide of 39 amino acids, engineered to activate both GIP and GLP‑1 receptors. A C20 fatty‑diacid chain attached to a lysine residue enables reversible binding to albumin, prolonging its action.

Structural Highlights

Chemical class

Synthetic peptide analogue

Based on human GIP sequence with modifications to resist degradation and add GLP‑1 activity.

Amino acids

39 amino acids

Includes a C20 fatty‑diacid moiety (eicosanedioic acid) attached to Lys20.

Molecular weight

~4.8 kDa

The large size and lipid chain delay renal filtration and extend half‑life.

Excipients and Their Roles

Ingredient	Purpose
Sodium phosphate dibasic heptahydrate	Buffer to maintain pH
Benzyl alcohol (E1519)	Preservative (5.4 mg per dose)
Glycerol	Tonicity agent
Phenol	Preservative
Sodium chloride	Tonicity adjustment
Water for injections	Solvent

🗒️ Pharmaceutical insight: The C20 fatty chain binds to serum albumin, protecting tirzepatide from rapid kidney clearance and allowing once‑weekly dosing.

Mechanism of Action: How Tirzepatide Works

Tirzepatide is a first‑in‑class dual GIP (glucose‑dependent insulinotropic polypeptide) and GLP‑1 (glucagon‑like peptide‑1) receptor agonist. It activates both pathways simultaneously, producing complementary effects on blood sugar and body weight.

Key Physiological Actions

Pancreas (beta cells): Increases insulin secretion only when glucose is high.
Pancreas (alpha cells): Suppresses glucagon release, reducing hepatic glucose output.
Brain: Activates receptors in the hypothalamus to enhance satiety and reduce food cravings.
Stomach: Slows gastric emptying, prolonging fullness after meals.
Adipose tissue: GIP may improve lipid storage and insulin sensitivity.

Comparison: Single vs Dual Agonism

Pathway	GLP‑1 alone	Dual GIP/GLP‑1 (tirzepatide)
Insulin secretion	++	+++ (synergistic)
Glucagon suppression	+	++
Appetite suppression	++	+++
Gastric emptying	++	++
Weight loss efficacy	~10–15%	~15–22% (SURMOUNT trials)

🗒️ Clinical insight: The addition of GIP agonism appears to amplify weight loss beyond GLP‑1 alone, possibly by direct effects on fat tissue and brain reward centres.

GIP and GLP‑1 Receptor Agonism Explained

GIP and GLP‑1 are incretin hormones released from the gut after eating. Tirzepatide’s unique structure allows it to bind potently to both receptors.

GLP‑1 receptor

Increases insulin (glucose‑dependent)
Suppresses glucagon
Slows gastric emptying
Reduces appetite (central action)

GIP receptor

Increases insulin (glucose‑dependent)
May enhance fat‑tissue insulin sensitivity
Potential direct effect on bone turnover
Reinforces satiety signals in the brain

The dual stimulation produces a more physiological response, mimicking the natural synergy of both incretins. This explains the superior HbA1c reduction and weight loss observed in trials.

Metabolic Effects and Duration in the Body

After subcutaneous injection, tirzepatide reaches peak concentration in about 24–48 hours. Its long half‑life (5 days) allows once‑weekly dosing.

Time course of action (steady state)

Week 1–2: Appetite suppression begins; blood glucose improves.
Week 4: Full therapeutic effect (steady state) after 2–4 doses.
Ongoing: Weight loss continues over months; maximal effect by 6–9 months.

Metabolic pathway

Tirzepatide is metabolised by general protein catabolism into small peptides and amino acids; no specific cytochrome P450 interactions are expected. Excretion occurs via both renal and biliary routes as metabolites.

🗒️ Pharmacokinetic note: Because of albumin binding, tirzepatide has a low clearance rate. Dose adjustments are not needed for mild‑moderate renal impairment, but caution is advised in severe kidney disease.

Absorption, Distribution & Elimination of Mounjaro

Parameter	Value
Bioavailability	≈80% after subcutaneous injection
Peak concentration	24–48 hours post‑dose
Protein binding	>99% (primarily albumin)
Volume of distribution	≈10.3 L
Half‑life	5 days (range 4–6 days)
Time to steady state	4 weeks (after 2–4 doses)
Elimination routes	Proteolytic degradation; metabolites in urine and faeces

Once‑weekly dosing maintains relatively stable concentrations, avoiding the peaks and troughs seen with daily injections.

Clinical Efficacy for Weight Loss and Type 2 Diabetes

The SURPASS (diabetes) and SURMOUNT (obesity) trials demonstrated robust outcomes:

Key trial results

SURMOUNT‑1: Up to 22.5% body weight reduction with 15 mg dose (vs 2.4% placebo).
SURPASS‑2: HbA1c reduction up to 2.4 percentage points; 12.4 kg weight loss at 15 mg.
SURMOUNT‑OSA: Significant improvement in obstructive sleep apnoea severity.

Efficacy is maintained over at least 2 years with continued treatment. When combined with diet and physical activity, Mounjaro helps achieve and sustain weight loss.

Mounjaro Mechanism FAQs

How does Mounjaro suppress appetite?

Mounjaro activates GLP‑1 receptors in the hypothalamus, the brain’s appetite centre, making you feel fuller and reducing hunger signals. GIP may also contribute to this effect.

How long does Mounjaro stay in your system?

The half‑life is about 5 days, so it takes roughly 30 days (5 half‑lives) for the drug to be completely cleared after your last injection.

Can Mounjaro cause low blood sugar (hypoglycaemia)?

On its own, the risk is low because it stimulates insulin only when glucose is high. However, if combined with sulfonylureas or insulin, hypoglycaemia can occur – your doctor may adjust those medications.

Why is Mounjaro injected only once a week?

The C20 fatty acid chain binds strongly to albumin, which acts as a circulating reservoir, slowly releasing tirzepatide over several days.

How does Mounjaro compare to Wegovy or Saxenda?

Mounjaro targets both GIP and GLP‑1, while Wegovy and Saxenda target only GLP‑1. Clinical trials show Mounjaro leads to greater average weight loss.

Ready to Start Your Weight Loss Journey?

If Mounjaro sounds like the right option for you, speak with a UK‑registered doctor through a confidential online consultation. We’ll help you understand if it’s suitable and guide you through the process.